Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study
Veterinary Research Communications · 2024
DOI: 10.1007/s11259-024-10400-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Research Communications, 2024. Verfasst von Ivone Izabel Mackowiak da Fonseca und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil. Hauptthemen laut MEDLINE: Mammary Neoplasms, Animal, Bacterial Toxins, Antigens, Bacterial, Dog Diseases. Die Arbeit nennt 71 Literaturangaben.
Abstract (Originalsprache)
Mammary tumors are the most frequent type of neoplasms in intact female dogs. New therapies that target neoplastic cells without affecting normal cells are highly sought. The Bacillus anthracis toxin has been reengineered to target tumor cells that express urokinase plasminogen activators and metalloproteinases. In previous studies carried out in our laboratory, the reengineered anthrax toxin had inhibitory effects on canine oral mucosal melanoma and canine osteosarcoma cells. In this study, five canine neoplastic epithelial cell lines (four adenocarcinomas and one adenoma) and one non-neoplastic canine mammary epithelial cell line were treated with different concentrations of reengineered anthrax toxin components. Cell viability was quantified using an MTT assay and half-maximal inhibitory concentration (IC50) values. Cell lines were considered sensitive when the IC50 was lower than 5000 ng/ml. One canine mammary adenocarcinoma cell line and one mammary adenoma cell line showed significantly decreased viability after treatment, whereas the non-neoplastic cell line was resistant. We conclude that the reengineered anthrax toxin may be considered a targeted therapy for canine mammary neoplasms while preserving normal canine mammary epithelial cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil.
- Global Vet Pathology, Montgomery Village, Maryland, MD, 20886, USA.
- Aging Institute and Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
- Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
- Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo, São Paulo, SP, 05508-270, Brazil. mlzdagli@usp.br.
Zitieren
APA
da Fonseca, I. I. M., Nagamine, M. K., Gentile, L. B., Nishiya, A. T., da Fonseca, J. M., de Oliveira Massoco, C., Ward, J. M., Liu, S., Leppla, S. H., & Dagli, M. L. Z. (2024). Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study. Veterinary Research Communications. https://doi.org/10.1007/s11259-024-10400-5
Vancouver
da Fonseca IIM, Nagamine MK, Gentile LB, Nishiya AT, da Fonseca JM, de Oliveira Massoco C, et al. Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study. Veterinary Research Communications. 2024. doi:10.1007/s11259-024-10400-5
BibTeX
@article{daFonseca2024,
author = {da Fonseca, Ivone Izabel Mackowiak and Nagamine, Márcia Kazumi and Gentile, Luciana Boffoni and Nishiya, Adriana Tomoko and da Fonseca, Jonathan Mackowiak and de Oliveira Massoco, Cristina and Ward, Jerrold Michael and Liu, Shihui and Leppla, Stephen Howard and Dagli, Maria Lucia Zaidan},
title = {Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study},
journal = {Veterinary Research Communications},
year = {2024},
doi = {10.1007/s11259-024-10400-5}
}
EUVIMED